The new issue of Oxurion Perspectives magazine is here. Read about last year's highlights and the ambitious times ahead.
Patrik De Haes, M.D., CEO of Oxurion, and Thomas Clay, Chairman of the Board, review the year 2019.
Arshad Khanani, M.D., M.A. about the clinical phase 1 data of THR-687.
Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.
Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.
“The new name comes from combining the words Oxygen and Orion”, explains CEO Patrik De Haes, MD. “Raising oxygen levels in cells plays a key role in helping prevent and reverse ...